Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 2
1991 11
1992 11
1993 18
1994 19
1995 131
1996 305
1997 428
1998 713
1999 711
2000 615
2001 603
2002 572
2003 573
2004 527
2005 540
2006 492
2007 563
2008 566
2009 483
2010 484
2011 518
2012 518
2013 466
2014 445
2015 402
2016 393
2017 320
2018 316
2019 316
2020 331
2021 241
2022 196
2023 185
2024 48

Text availability

Article attribute

Article type

Publication date

Search Results

12,328 results

Results by year

Filters applied: . Clear all
Page 1
HIV treatment and prevention 2019: current standards of care.
Phanuphak N, Gulick RM. Phanuphak N, et al. Curr Opin HIV AIDS. 2020 Jan;15(1):4-12. doi: 10.1097/COH.0000000000000588. Curr Opin HIV AIDS. 2020. PMID: 31658110 Review.
PURPOSE OF REVIEW: The purpose of this review is to summarize the current standards of care for both HIV treatment and HIV prevention in 2019. RECENT FINDINGS: Current HIV treatment is started as soon as feasible in a person with HIV infection and cons …
PURPOSE OF REVIEW: The purpose of this review is to summarize the current standards of care for both HIV treatment and HIV pre …
Amprenavir.
Adkins JC, Faulds D. Adkins JC, et al. Drugs. 1998 Jun;55(6):837-42; discussion 843-4. doi: 10.2165/00003495-199855060-00015. Drugs. 1998. PMID: 9617598 Review.
Amprenavir is a viral protease inhibitor with specificity for the HIV protease enzyme. The resistance profile of amprenavir appears to differ from that of other protease inhibitors such as saquinavir and indinavir. ...In a small nonblind …
Amprenavir is a viral protease inhibitor with specificity for the HIV protease enzyme. The resistance profile of …
Warfarin-antiretroviral interactions.
Liedtke MD, Rathbun RC. Liedtke MD, et al. Ann Pharmacother. 2009 Feb;43(2):322-8. doi: 10.1345/aph.1L497. Epub 2009 Feb 5. Ann Pharmacother. 2009. PMID: 19196837 Review.
DATA SOURCES: Primary literature was identified through a search of MEDLINE (1950-July 2008) and International Pharmaceutical Abstracts (1970-July 2008) using individual antiretroviral drug names and the following key search terms: warfarin, antiretroviral, protease inh …
DATA SOURCES: Primary literature was identified through a search of MEDLINE (1950-July 2008) and International Pharmaceutical Abstracts (197 …
Darunavir: A comprehensive profile.
Darwish IA, Al-Majed AA, Alsaif NA, Bakheit AH, Herqash RN, Alzaid A. Darwish IA, et al. Profiles Drug Subst Excip Relat Methodol. 2021;46:1-50. doi: 10.1016/bs.podrm.2020.07.001. Epub 2020 Aug 21. Profiles Drug Subst Excip Relat Methodol. 2021. PMID: 33461696 Review.
Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]carbamate is a synthetic non-peptide protease inhibitor. On June 2006, it was first approved by the Food and Drug administratio …
Darunavir: (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl [(2S,3R)-4-{[(4-aminophenyl)sulfonyl] (isobutyl)amino}-3-hydroxy-1-phenyl-2-butanyl]c …
Darunavir : a nonpeptidic protease inhibitor for antiretroviral-naive and treatment-experienced adults with HIV infection.
Robertson J, Feinberg J. Robertson J, et al. Expert Opin Pharmacother. 2012 Jun;13(9):1363-75. doi: 10.1517/14656566.2012.681776. Epub 2012 May 17. Expert Opin Pharmacother. 2012. PMID: 22594781 Review.
INTRODUCTION: Darunavir , a nonpeptidic inhibitor of the HIV-1 protease with potent activity against resistant virus, was initially approved by the FDA (2006) and the EMA (2007) for the treatment of antiretroviral-experienced adults, and later for naive adult …
INTRODUCTION: Darunavir , a nonpeptidic inhibitor of the HIV-1 protease with potent activity against resistant virus, w …
[Anti-HIV drugs].
Koibuchi T. Koibuchi T. Uirusu. 2013;63(2):199-208. doi: 10.2222/jsv.63.199. Uirusu. 2013. PMID: 25366054 Free article. Review. Japanese.
Anti-HIV drugs are fall into the following 5 categories: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs), integrase strand transfer inh …
Anti-HIV drugs are fall into the following 5 categories: nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) …
A Combination of Novel HIV-1 Protease Inhibitor and Cytochrome P450 (CYP) Enzyme Inhibitor to Explore the Future Prospective of Antiviral Agents: Evotaz.
Sharma A, Sharma P, Kapila I, Abbot V. Sharma A, et al. Curr HIV Res. 2023;21(3):149-159. doi: 10.2174/1570162X21666230522123631. Curr HIV Res. 2023. PMID: 37221692 Review.
In the continuous search for better antiviral agents, the United States Food and Drug Administration (USFDA) approved a new drug named Evotaz on January 29, 2015 for the treatment of human immunodeficiency virus (HIV). Evotaz is a combined once-daily fixed drug, con …
In the continuous search for better antiviral agents, the United States Food and Drug Administration (USFDA) approved a new drug name …
[Modern HIV treatment].
Lehmann C, Malin J, Suárez I, Fätkenheuer G. Lehmann C, et al. Internist (Berl). 2019 Apr;60(4):411-419. doi: 10.1007/s00108-019-0564-0. Internist (Berl). 2019. PMID: 30778612 Review. German.
The regimen contains two nucleoside reverse transcriptase inhibitors plus either an integrase inhibitor, a boosted protease inhibitor, or a non-nucleoside reverse transcriptase inhibitor. ...Novel approaches for HIV therapy include dual t …
The regimen contains two nucleoside reverse transcriptase inhibitors plus either an integrase inhibitor, a boosted protease …
Computer-Aided Optimization of Combined Anti-Retroviral Therapy for HIV: New Drugs, New Drug Targets and Drug Resistance.
Zazzi M, Cozzi-Lepri A, Prosperi MC. Zazzi M, et al. Curr HIV Res. 2016;14(2):101-9. doi: 10.2174/1570162x13666151029102254. Curr HIV Res. 2016. PMID: 26511342 Review.
METHODS: Experts' rules and statistical/machine learning algorithms for interpreting HIV drug resistance, along with their program implementations, were retrieved from PubMed and other on-line resources to be critically reviewed in terms of technical approach, performance, …
METHODS: Experts' rules and statistical/machine learning algorithms for interpreting HIV drug resistance, along with their program im …
Antiretroviral agents in pre-exposure prophylaxis: emerging and advanced trends in HIV prevention.
Yap PK, Loo Xin GL, Tan YY, Chellian J, Gupta G, Liew YK, Collet T, Dua K, Chellappan DK. Yap PK, et al. J Pharm Pharmacol. 2019 Sep;71(9):1339-1352. doi: 10.1111/jphp.13107. Epub 2019 May 29. J Pharm Pharmacol. 2019. PMID: 31144296 Review.
OBJECTIVES: Antiretroviral agents (ARVs) have been the most promising line of therapy in the management of human immunodeficiency virus (HIV) infections. ...SUMMARY: Some of the most common pre-exposure prophylactic strategies employed currently are the use o …
OBJECTIVES: Antiretroviral agents (ARVs) have been the most promising line of therapy in the management of human immunodeficiency vir …
12,328 results
You have reached the last available page of results. Please see the User Guide for more information.